Naloxone Bioavailability
Naloxone Bioavailability is the proportion of an administered dose of naloxone that reaches the systemic circulation unchanged, serving as a pharmacokinetic metric to quantify the rate and extent of active drug absorption into the body.
22
Publications
1.7K
Citations
100
Authors
44
Institutions
Publications per year
2017–2026
10
Parents
22
Oral naloxone reverses opioid-associated constipation
U. Schmidt, Michael Hartmann, R. Kath et al. · Pain · 2000 · 203 citations
Ramesh Panchagnula, Pramod S. Salve, Narisetty Sunil Thomas et al. · International Journal of Pharmaceutics · 2001 · 136 citations
1–5 of 22
100
2
h-index
National Institute of Pharmaceutical Education and Research, India
2 publications · 170 citations
2
h-index
2
h-index
University at Buffalo, State University of New York, United States
2 publications · 348 citations
2
h-index
National Institute of Pharmaceutical Education and Research, India
2 publications · 170 citations
2
h-index
1–5 of 100
44
Mundipharma (United Kingdom)
Cambridge, United Kingdom
2 h-index
3 publications
152 citations
DuPont (United States)
Wilmington, United States
2 h-index
7 publications
1.1K citations

Johns Hopkins Medicine
Baltimore, United States
2 h-index
2 publications
99 citations

Johns Hopkins University
Baltimore, United States
2 h-index
2 publications
99 citations
National Institute of Pharmaceutical Education and Research
Mohali, India
2 h-index
6 publications
714 citations

University of Palermo
Palermo, Italy
1 h-index
5 publications
230 citations
Washington State University Spokane
Spokane, United States
1 h-index
5 publications
70 citations
Norwegian University of Science and Technology
Trondheim, Norway
1 h-index
7 publications
147 citations
1–8 of 44
4 publications · 518 citations
4
h-index
2 publications · 157 citations
2
h-index
JAPhA · 2 publications · 66 citations
2
h-index
1 publications · 40 citations
1
h-index
1 publications · 100 citations
1
h-index
1–5